This page respects the original work's rights terms and independently introduces its bibliography, abstract, main results, and limitations. It is not a full translation.
About this resource
This page introduces a 2020 study that reassessed participants from an earlier psilocybin trial for psychological and existential distress associated with life-threatening cancer several years later. Fifteen people took part in the long-term follow-up, with the first follow-up at a mean of 3.2 years and the second at a mean of 4.5 years. Depression, anxiety, attitudes toward death, quality of life, and the personal and spiritual meaning of the earlier experience were assessed.
Long-term follow-up is valuable for considering persistence, but the randomized controlled comparison had already been lost. The findings are self-reports from a small selected group of survivors and respondents and cannot establish that psilocybin causally produced outcomes years later.
Study design
The research team contacted participants from the preceding randomized crossover trial and administered standardized psychiatric-symptom scales, life and existential measures, and questions about the meaning of the experience. Responses were collected at 2 long-term time points and descriptively compared with results from the earlier trial.
Everyone had experienced the psilocybin condition in the preceding trial, leaving no long-term unexposed group. Cancer progression and treatment, psychotherapy, medication, family and social environments, and subsequent life experiences were not controlled.
Content
The study asks whether the meaning of an intense single experience remains with a person years later and to what extent improvement in psychiatric symptoms is seen at long-term time points. Participants’ illness and survival status make the long-term sample itself a selected subgroup.
“Sustained meaning” and “a pharmacological effect persisting in the body” are different. Memory of the experience, retelling, support, and changes in life contribute to long-term evaluations.
Results
Many follow-up participants continued to rate the earlier session as personally meaningful and spiritually important. Some had depression and anxiety scores below their pretrial levels. The authors interpreted the findings as a signal that improvement and subjective meaning might be maintained over the long term.
An uncontrolled follow-up of 15 people, however, cannot separate natural course, additional treatment, survivor bias, or respondent selection. Outcomes of people who did not participate or had died could not be evaluated in the same way.
Limitations
The sample was extremely small, and there was no control group at long-term time points. Participants came from one preceding trial at a single site and were affected by selection and expectations. Memory, current condition, and the process of finding meaning in the experience can influence self-report.
This was not a large cohort designed for systematic long-term safety surveillance and cannot evaluate rare psychiatric or physical harms. It also did not test effects on cancer-treatment outcomes or survival.
The phrase “mean 4.5 years” does not mean every participant was assessed at the same interval. Individual follow-up periods and illness status differed.
Safety
A predominance of positive evaluations at long-term follow-up does not mean the intervention is safe or reproducible for everyone or effective against cancer. The preceding trial included exclusions, preparation, monitoring, and psychological support. Conditions differ in general environments and with mushroom products.
This page does not guide ingestion, changes to cancer treatment, or discontinuation of psychiatric care. Both existential distress and medical urgency need attention, with ordinary support pathways taking priority.
Source and rights
Original source: Agin-Liebes GI, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of Psychopharmacology. 2020;34(2):155–166. DOI: 10.1177/0269881119897615.
Respecting the publisher’s copyright, this page is a detailed introduction that independently summarizes study design, results, and limitations based on public bibliographic information and the abstract. It is not a full translation or republication of figures and tables.